Last Updated: October 3, 2025
Analyzing Management
Public company leadership plays a pivotal role for hedge funds and asset managers, both during initial due diligence and in ongoing risk assessment. ManagementTrack offers a consistent methodology that eliminates distractions—highlighting distinct strengths and weaknesses, identifying warning signs and positive indicators, and establishing a tangible connection between CEO actions and investment performance.
CEO van de Winkel’s execution risk threatens to offset EPKINLY’s commercial success
Analysis of Genmab CEO Jan van de Winkel
Despite successful commercial execution with EPKINLY, a history of late-stage pipeline failures and lost arbitrations raises execution risk for offsetting the company’s upcoming patent cliff and maximizing new pipeline value.
Management evaluated Jan van de Winkel’s track record and skillset against the following key factors for GMAB-DK:
- Executing the accelerated Rina-S clinical development plan.
- Building a new pipeline to offset the DARZALEX patent cliff.
- Executing the EPKINLY launch to prove commercial capability.
- Maintaining DARZALEX/Kesimpta sales to fund the pipeline.
Jan van de Winkel’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
As van de Winkel shifts from a capital-efficient partnership model to a debt-fueled M&A strategy, how does he balance his deep scientific conviction in an asset against the immense financial risks and integration challenges of a “bet-the-company” acquisition?
Question #2
Given the history of significant late-stage pipeline failures that necessitated the pivot to M&A, does van de Winkel possess the operational rigor to hold his teams accountable for execution, or does his scientific passion cause him to protect promising but ultimately flawed assets for too long?
Question #3
When faced with a critical conflict with a powerful partner, as seen in the lost Janssen arbitrations, does van de Winkel’s instinct for scientific collaboration undermine his ability to take the tough, adversarial stance required to maximize shareholder value?
Why Do Investors Use ManagementTrack?
What is ManagementTrack’s analysis of GMAB-DK’s CEO, Jan van de Winkel?
Through its proprietary career analysis and interviews with former colleagues, ManagementTrack establishes an executive’s track record, identifying key strengths and weaknesses. This profile is then measured against GMAB-DK’s most critical challenges: executing the accelerated Rina-S clinical development plan and the EPKINLY launch, building a new pipeline to offset the DARZALEX patent cliff, and maintaining sales of DARZALEX and Kesimpta to fund the pipeline.
Beyond career analysis, what other tools does ManagementTrack use to assess management’s impact on future performance?
ManagementTrack utilizes additional proprietary tools to evaluate leadership. Its models are designed to detect unusual levels of executive evasion during earnings call Q&A sessions. Furthermore, ManagementTrack scrutinizes all insider transactions to identify outlier activity that signals potential future stock over or underperformance. These inputs, combined with the ManagementTrack Rating—a predictive 1-to-10 score for each executive—provide investors with a distinct, data-driven perspective on how management’s capabilities are likely to influence company performance.
What is the scope of ManagementTrack’s coverage?
ManagementTrack provides real-time analysis on the c-suite executives of all publicly traded companies.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Jan van de Winkel
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- Genmab A/S 10Q
- Genmab A/S 10K
- Genmab A/S Earnings Calls
- Genmab A/S Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
